BigHat Biosciences
BigHat Biosciences runs an AI-enabled antibody discovery and engineering platform that pairs a high-speed wet lab with machine learning. It builds an internal therapeutic pipeline and works with pharma partners including Amgen and Lilly (collaboration announced April 2025). It raised a $75M Series B in 2022, bringing total funding to $100M at the time, and CB Insights puts total raised at about $145M after a later $45M Series B extension. The company was founded in 2019 by CEO Mark DePristo and CSO Peyton Greenside.
Funding
Every round, secondary, debt facility or acquisition involving BigHat Biosciences that AI Lounge tracks, newest first. Latest: Series C on Sep 24, 2026.
Timeline · 2
In the news
Members see every AI company on AI Lounge with revenue, funding, valuation and investors, searchable and sortable, free.
Create my free account →Log in